Faeth Therapeutics, Inc.
No enriched coverage for $FTH in the last 7 days.
No SEC Form 4 filings for $FTH in the last 30 days.
See all $FTH insider activity →Analysts initiated coverage on five companies. Baird rated Hubbell (HUBB) Outperform with a $550 target. BMO rated Nvidia (NVDA) Outperform with a $340 target. Needham rated Faeth Therapeutics (FTH) Buy with a $56 target. Citizens rated Builders FirstSource (BLDR) Market Perform. Cantor Fitzgerald rated Nuvation Bio (NUVB) Overweight.
Faeth Therapeutics (FTH) shares rose 5.8% after the FDA granted Fast Track designation to PIKTOR, an investigational all-oral combo of sapanisertib and serabelisib with paclitaxel for advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations. The article cites a $54.50 consensus 12-month target and Phase 2 PIK-201 topline data expected by year-end 2026.
Faeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates — Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — — Comp
Recent FTH coverage spans financial news, insider activity and regulation.
Coverage may lift a small‑cap biotech.
FDA Fast Track status is a near-term positive catalyst for FTH by potentially accelerating development and review toward Phase 2 topline data.
The 8-K discloses a major balance-sheet step-up plus updated clinical timelines, which can reset near-term risk and funding expectations.
The 8-K discloses equity compensation terms tied to a $70 average closing-price hurdle, which can affect near-term sentiment and option valuation.
Pipeline progression supports long-duration upside optionality, but the article provides no new interim data yet.
alphai scores every news story that mentions FTH with an AI model for sentiment and relevance, and aggregates insider trades from Faeth Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Analysts initiated coverage on five companies. Baird rated Hubbell (HUBB) Outperform with a $550 target. BMO rated Nvidia (NVDA) Outperform with a $340 target. Needham rated Faeth Therapeutics (FTH) Buy with a $56 target. Citizens rated Builders FirstSource (BLDR) Market Perform. Cantor Fitzgerald rated Nuvation Bio (NUVB) Overweight.
1 min readFaeth Therapeutics (FTH) shares rose 5.8% after the FDA granted Fast Track designation to PIKTOR, an investigational all-oral combo of sapanisertib and serabelisib with paclitaxel for advanced or recurrent endometrial cancer with PI3K/AKT/mTOR pathway alterations. The article cites a $54.50 consensus 12-month target and Phase 2 PIK-201 topline data expected by year-end 2026.
3 min readFaeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates — Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end — — First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer — — Comp
6 min readFaeth Therapeutics, Inc. (FTH) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001829802 0001829802 2026-07-21 2026-07-21 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21,
2 min readBiotech stocks hit 52-week highs on July 10, 2026. American Well (AMWL) reached $10.16, citing Nature coverage of SilverCloud and insurer-related deals, and guided 2026 revenue to $195M-$205M. Cue Biopharma (CUE) hit $45.50 amid a ~$50M private placement. ImmuCell (ICCC) rose to $11.59 after Q2 sales of $7.2M. Scholar Rock (SRRK) hit $58.49 on BLA acceptance for apitegromab, with FDA response due by Sept. 30. Faeth (FTH) touched $36.89 on PIKTOR trial timelines.
5 min readInvesting.com roundup of US insider trades: Jewett-Cameron (JCTC) 10% owners bought $806k (353,607 shares) June 29; RH director bought 11,388 shares for $1.83m; Faeth Therapeutics CFO bought 13,634 shares for $326k; GitLab CEO bought 4,188 shares for $123k. Sells: Oruka (ORKA) fund sold 3.55m shares for $300m; AMAT CEO sold 78,321 shares ~$55.5m; Airbnb director sold 294,903 shares ~$43.8m; Snowflake director sold 99,900 shares ~$25.1m; Workday owner sold 107,500 shares ~$13.1m.
6 min readSTEPHENSON BRIAN C (Chief Financial Officer) purchased 13,634 indirectly-held shares of Faeth Therapeutics, Inc. (FTH) at an average of $23.92 ($22.95–$24.98, $0.33M total) across 6 trades over 2026-06-29 to 2026-07-01.
2 min readRobert W. Baird upgraded Sensei Biotherapeutics (NASDAQ:FTH) to a “strong-buy” rating, according to Zacks.com. Other firms issued mixed views: BTIG also set “strong-buy,” HC Wainwright initiated with a $60 target, and Weiss Ratings began with a “sell (d-)” rating. FTH opened at $22.87; MarketBeat cites an average “Buy” rating and $58.50 target.
4 min readSTEPHENSON BRIAN C (Chief Financial Officer) purchased 15,641 indirectly-held shares of Faeth Therapeutics, Inc. (SNSE) at an average of $25.65 ($23.61–$27.77, $0.40M total) across 8 trades over 2026-06-24 to 2026-06-26.
2 min readSTEPHENSON BRIAN C (Chief Financial Officer) purchased 17,413 indirectly-held shares of Faeth Therapeutics, Inc. (SNSE) at an average of $23.31 ($20.23–$25.91, $0.41M total) across 8 trades over 2026-06-22 to 2026-06-23.
2 min read
